guest ::
| Home > Institute Collections > UL DZNE > UL DZNE-AG Danzer > Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease. > print |
| Home > Institute Collections > UL DZNE > UL DZNE-AG Danzer > Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease. > print |
| 001 | 155805 | ||
| 005 | 20240205112133.0 | ||
| 024 | 7 | _ | |2 doi |a 10.1002/ana.25557 |
| 024 | 7 | _ | |2 pmid |a pmid:31343083 |
| 024 | 7 | _ | |2 ISSN |a 0364-5134 |
| 024 | 7 | _ | |2 ISSN |a 1531-8249 |
| 037 | _ | _ | |a DZNE-2021-00965 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |0 P:(DE-2719)9001519 |a Grozdanov, Veselin |b 0 |u dzne |
| 245 | _ | _ | |a Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease. |
| 260 | _ | _ | |a Hoboken, NJ |b Wiley-Blackwell |c 2019 |
| 336 | 7 | _ | |2 DRIVER |a article |
| 336 | 7 | _ | |2 DataCite |a Output Types/Journal article |
| 336 | 7 | _ | |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |a Journal Article |b journal |m journal |s 1684225545_1958 |
| 336 | 7 | _ | |2 BibTeX |a ARTICLE |
| 336 | 7 | _ | |2 ORCID |a JOURNAL_ARTICLE |
| 336 | 7 | _ | |0 0 |2 EndNote |a Journal Article |
| 520 | _ | _ | |a Excessive inflammation in the central nervous system (CNS) and the periphery can result in neurodegeneration and parkinsonism. Recent evidence suggests that immune responses in Parkinson disease patients are dysregulated, leading to an increased inflammatory reaction to unspecific triggers. Although α-synuclein pathology is the hallmark of Parkinson disease, it has not been investigated whether pathologic α-synuclein is a specific trigger for excessive inflammatory responses in Parkinson disease.We investigated the immune response of primary human monocytes and a microglial cell line to pathologic forms of α-synuclein by assessing cytokine release upon exposure.We show that pathologic α-synuclein (mutations, aggregation) results in a robust inflammatory activation of human monocytes and microglial BV2 cells. The activation is conformation- dependent, with increasing fibrillation and early onset mutations having the strongest effect on immune activation. We also found that activation of immune cells by extracellular α-synuclein is potentiated by extracellular vesicles, possibly by facilitating the uptake of α-synuclein. Blood extracellular vesicles from Parkinson disease patients induce a stronger activation of monocytes than blood extracellular vesicles from healthy controls. Most importantly, monocytes from Parkinson disease patients are dysregulated and hyperactive in response to stimulation with pathologic α-synuclein. Furthermore, we demonstrate that α-synuclein pathology in the CNS is sufficient to induce the monocyte dysregulation in the periphery of a mouse model.Taken together, our data suggest that α-synuclein pathology and dysregulation of monocytes in Parkinson disease can act together to induce excessive inflammatory responses to α-synuclein. ANN NEUROL 2019;86:593-606. |
| 536 | _ | _ | |0 G:(DE-HGF)POF4-352 |a 352 - Disease Mechanisms (POF4-352) |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |2 NLM Chemicals |a Cytokines |
| 650 | _ | 7 | |2 NLM Chemicals |a alpha-Synuclein |
| 650 | _ | 2 | |2 MeSH |a Animals |
| 650 | _ | 2 | |2 MeSH |a Cells, Cultured |
| 650 | _ | 2 | |2 MeSH |a Cytokines: metabolism |
| 650 | _ | 2 | |2 MeSH |a Extracellular Vesicles: immunology |
| 650 | _ | 2 | |2 MeSH |a Humans |
| 650 | _ | 2 | |2 MeSH |a Inflammation: complications |
| 650 | _ | 2 | |2 MeSH |a Inflammation: metabolism |
| 650 | _ | 2 | |2 MeSH |a Mice |
| 650 | _ | 2 | |2 MeSH |a Mice, Transgenic |
| 650 | _ | 2 | |2 MeSH |a Microglia: metabolism |
| 650 | _ | 2 | |2 MeSH |a Monocytes: metabolism |
| 650 | _ | 2 | |2 MeSH |a Mutation |
| 650 | _ | 2 | |2 MeSH |a Parkinson Disease: immunology |
| 650 | _ | 2 | |2 MeSH |a Parkinson Disease: metabolism |
| 650 | _ | 2 | |2 MeSH |a alpha-Synuclein: adverse effects |
| 650 | _ | 2 | |2 MeSH |a alpha-Synuclein: genetics |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Bousset, Luc |b 1 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Hoffmeister, Meike |b 2 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Bliederhaeuser, Corinna |b 3 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Meier, Christoph |b 4 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Madiona, Karine |b 5 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Pieri, Laura |b 6 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kiechle, Martin |b 7 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a McLean, Pamela J |b 8 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Kassubek, Jan |b 9 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Behrends, Christian |b 10 |
| 700 | 1 | _ | |0 P:(DE-2719)2812633 |a Ludolph, Albert |b 11 |u dzne |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Weishaupt, Jochen H |b 12 |
| 700 | 1 | _ | |0 P:(DE-HGF)0 |a Melki, Ronald |b 13 |
| 700 | 1 | _ | |0 P:(DE-2719)9001513 |a Danzer, Karin M |b 14 |e Last author |u dzne |
| 773 | _ | _ | |0 PERI:(DE-600)2037912-2 |a 10.1002/ana.25557 |g Vol. 86, no. 4, p. 593 - 606 |n 4 |p 593 - 606 |t Annals of neurology |v 86 |x 1531-8249 |y 2019 |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155805/files/DZNE-2021-00965.pdf |y OpenAccess |
| 856 | 4 | _ | |u https://pub.dzne.de/record/155805/files/DZNE-2021-00965.pdf?subformat=pdfa |x pdfa |y OpenAccess |
| 909 | C | O | |o oai:pub.dzne.de:155805 |p openaire |p open_access |p driver |p dnbdelivery |
| 910 | 1 | _ | |0 I:(DE-HGF)0 |6 P:(DE-2719)9001519 |a External Institute |b 0 |k Extern |
| 910 | 1 | _ | |0 I:(DE-HGF)0 |6 P:(DE-2719)2812633 |a External Institute |b 11 |k Extern |
| 910 | 1 | _ | |0 I:(DE-HGF)0 |6 P:(DE-2719)9001513 |a External Institute |b 14 |k Extern |
| 913 | 1 | _ | |0 G:(DE-HGF)POF4-352 |1 G:(DE-HGF)POF4-350 |2 G:(DE-HGF)POF4-300 |3 G:(DE-HGF)POF4 |4 G:(DE-HGF)POF |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |v Disease Mechanisms |x 0 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0200 |2 StatID |a DBCoverage |b SCOPUS |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0160 |2 StatID |a DBCoverage |b Essential Science Indicators |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1050 |2 StatID |a DBCoverage |b BIOSIS Previews |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1190 |2 StatID |a DBCoverage |b Biological Abstracts |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0600 |2 StatID |a DBCoverage |b Ebsco Academic Search |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0100 |2 StatID |a JCR |b ANN NEUROL : 2019 |d 2021-02-03 |
| 915 | _ | _ | |0 LIC:(DE-HGF)CCBYNC4 |2 HGFVOC |a Creative Commons Attribution-NonCommercial CC BY-NC 4.0 |
| 915 | _ | _ | |0 StatID:(DE-HGF)3001 |2 StatID |a DEAL Wiley |d 2021-02-03 |w ger |
| 915 | _ | _ | |0 StatID:(DE-HGF)1030 |2 StatID |a DBCoverage |b Current Contents - Life Sciences |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0113 |2 StatID |a WoS |b Science Citation Index Expanded |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0150 |2 StatID |a DBCoverage |b Web of Science Core Collection |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0510 |2 StatID |a OpenAccess |
| 915 | _ | _ | |0 StatID:(DE-HGF)0030 |2 StatID |a Peer Review |b ASC |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)9905 |2 StatID |a IF >= 5 |b ANN NEUROL : 2019 |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0300 |2 StatID |a DBCoverage |b Medline |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)1110 |2 StatID |a DBCoverage |b Current Contents - Clinical Medicine |d 2021-02-03 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0420 |2 StatID |a Nationallizenz |d 2021-02-03 |w ger |
| 915 | _ | _ | |0 StatID:(DE-HGF)0199 |2 StatID |a DBCoverage |b Clarivate Analytics Master Journal List |d 2021-02-03 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-2719)5000072 |
| 980 | _ | _ | |a I:(DE-2719)1040260 |
| 980 | 1 | _ | |a UNRESTRICTED |
| 980 | 1 | _ | |a EXTERN4VITA |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|